TUCSON, Ariz. - A preliminary study of the active ingredient in psychedelic mushrooms has found it is effective in relieving the symptoms of people suffering from severe obsessive compulsive disorder, a University of Arizona psychiatrist reports.
Dr. Francisco A. Moreno led the first FDA-approved clinical study of psilocybin since it was outlawed in 1970. The results of the small-scale study are published in the latest edition of the Journal of Clinical Psychiatry.